The drug is used to treat ovarian cancer and Multiple myeloma or skin cancer. As 
you can read here new shipments will not ship until late August so you know what this means, hospitals sharing supplies and oncologists spending hours every week to ensure supplies for those currently being treated. This is what occurs at UCLA every day. You can read the official letter in pdf format here. BD
Drug Shortages Continue–UCLA Spends 2 Hours A Day Checking on Cancer Drug Availability–ASHP Website Lists All Current Shortages
NEW YORK - Johnson & Johnson has cautioned doctors not to begin treatment with its Doxil cancer drug because of shortages of the medicine made by an outside manufacturer.
The company had informed doctors last month about a potential shortage of the injectable medicine, made by a unit of German drugmaker Boehringer Ingelheim.
In a "Dear Healthcare Provider" letter posted this week on the drug's website, www.doxil.com, J&J confirmed that a shortage indeed now exists and that new supplies of the medicine will not be shipped until late August.
"Supplies may be intermittently available in the weeks thereafter," the letter said. "Until then, we advise that no new patients begin treatment with Doxil."
The injectable drug, which has annual global sales of about $500 million, is used to treat ovarian cancer and multiple myeloma.
Other product shortages recently cited by the FDA include Telecris Biotherapeutics Inc's form of human immune globulin and a number of products sold by Merck & Co -- including treatments for black widow spider bites, to prevent shingles and to prevent hepatitis A and hepatitis B.
0 comments :
Post a Comment